<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1537">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387890</url>
  </required_header>
  <id_info>
    <org_study_id>5566</org_study_id>
    <nct_id>NCT04387890</nct_id>
  </id_info>
  <brief_title>Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers</brief_title>
  <official_title>Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will follow a single prospective cohort of 50 Health Care Workers in the
      Hospital Italiano de Buenos Aires (Argentina) from May 15th to August 31st 2020 using
      antibody testing for SARS-CoV-2 IgM and IgG at baseline and every 2 weeks in order to assess
      the incidence of COVID-19, the prevalence of anti-SARS-CoV-2 antibodies (IgM and IgG) and
      incidence of reinfection or reactivations of previous COVID-19 using viral gene sequencing in
      this cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-CoV-2 infection in healthcare workers (HCW) is nowadays a frequent problem for patient
      care and organization of care teams. SARS-CoV-2 antibody assessment provides a tool to
      evaluate antibody prevalence in hospital staff identifying previously exposed individuals.
      Serologic testing could identify new cases of COVID-19 in an early fashion and could help to
      investigate cases of reactivation or reinfection in hospital workers. The study purpose is to
      conduct a study using serological screening for health care workers in a University Hospital
      in Buenos Aires in order to assess the risk of COVID-19 on those who have not developed an
      immune response against the virus, or to detect it in an early fashion (either
      pre-symptomatic or asymptomatic). If a study participant is suspected to have potential
      reinfection or reactivation of COVID-19, the investigators will conduct genome sequencing in
      order to be able to differentiate each case. The investigators will include 50 participants
      chosen at random among health care workers from the hospital Emergency Department (ED),
      Internal Medicine wards, or Critical Care Units who are exposed to COVID-19. Participants who
      agree to join the study and sign the informed consent form will be screened at baseline for
      SARS-CoV-2 IgM and IgG antibodies, along with a physical exam and basic laboratory
      determinations. They will be re-screened with antibodies every 2 weeks for a total of 3
      months. If they contract COVID-19, antibody determinations and nasopharyngeal swabs will be
      carried out in order to identify those who are in favorable conditions to return to work. The
      main objective is to prospectively determine the incidence of COVID-19, Anti SARS-CoV-2
      antibody prevalence, and incidence of SARS-CoV-2 reinfection or reactivation of COVID-19 in a
      health care workers cohort.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of anti SARS-CoV-2 antibodies (IgM and IgG) in health personnel</measure>
    <time_frame>Baseline at study inclussion</time_frame>
    <description>Patients that has a positive result for IgM or IgG at baseline first test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID-19 incidence through serology-based screening and/or compatible symptoms in health personnel previously known to be unexposed to the virus</measure>
    <time_frame>During 3 months follow up</time_frame>
    <description>Patients that has a positive result for IgM or IgG or PCR during follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of reactivation/reinfection for COVID-19 in health personnel with a positive serology for SARS-CoV-2</measure>
    <time_frame>During 3 months follow up</time_frame>
    <description>Patients with confirmed previous SARS Cov 2 antibodies that reactivate symptomons or new increase in antibodies title during follow up</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Health Personnel</condition>
  <arm_group>
    <arm_group_label>Serologic Screening</arm_group_label>
    <description>Participants will be screened for IgM and IgG SARS-CoV-2 antibodies at baseline and every 2 weeks. Participants showing symptoms compatible with COVID-19 will undergo nasopharyngeal swab for PCR testing for diagnosis. Participants recovered from COVID-19 will have to have 2 negative and consecutive nasopharyngeal swab PCR tests in order to return to work.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serologic SARS-CoV-2 screening</intervention_name>
    <description>Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up</description>
    <arm_group_label>Serologic Screening</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Physicians directed involved with the healthcare of COVID-19 patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthcare staff (Physicians) AND

          2. Directly involved in care of patients with confirmed or suspected COVID-19 AND

          3. Working in any of the two hospital venues (Hospital Italiano Central and Hospital
             Italiano San Justo Agust√≠n Rocca).

        Exclusion Criteria:

          1. Refusal to sign the Informed Consent Form OR

          2. Experienced symptoms compatible with COVID-19 in the last 14 days prior to eligibility
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leticia Peroni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIBA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanina Stanek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIBA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Sanchez Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIBA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ines Staneloni, MD</last_name>
    <phone>+54 011 4959 0200</phone>
    <email>maria.staneloni@hospitalitaliano.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Elizondo, MD</last_name>
    <email>cristina.elizondo@hospitalitaliano.org.ar</email>
  </overall_contact_backup>
  <link>
    <url>https://www.paho.org/arg/index.php?option=com_content&amp;view=article&amp;id=10436:la-oms-caracteriza-a-covid-19-como-una-pandemia&amp;Itemid=226</url>
    <description>OPS/OMS Argentina - La OMS caracteriza a COVID-19 como una pandemia</description>
  </link>
  <link>
    <url>https://www.argentina.gob.ar/coronavirus/informe-diario</url>
    <description>Informe diario. In: Argentina.gob.ar</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</url>
    <description>Novel Coronavirus (2019-nCoV) situation reports</description>
  </link>
  <link>
    <url>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200411-sitrep-82-covid-19.pdf?sfvrsn=74a5d15_2</url>
    <description>World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report</description>
  </link>
  <link>
    <url>http://www.cdc.gov/coronavirus/2019-ncov/hcp/return-to-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhealthcare-facilities%2Fhcp-return-work.html</url>
    <description>Coronavirus Disease 2019 (COVID-19). In: Centers for Disease Control and Prevention</description>
  </link>
  <link>
    <url>http://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolation</url>
    <description>Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 - first update. In: European Centre for Disease Prevention and Control</description>
  </link>
  <results_reference>
    <citation>The Lancet. COVID-19: protecting health-care workers. Lancet. 2020 Mar 21;395(10228):922. doi: 10.1016/S0140-6736(20)30644-9.</citation>
    <PMID>32199474</PMID>
  </results_reference>
  <results_reference>
    <citation>Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13. Review.</citation>
    <PMID>32178769</PMID>
  </results_reference>
  <results_reference>
    <citation>Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Chisty Z, Bell JM, Methner M, Harney J, Jacobs JR, Carlson CM, McLaughlin HP, Stone N, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Russell D, Hiatt B, Gant J, Duchin JS, Clark TA, Honein MA, Reddy SC, Jernigan JA; Public Health - Seattle &amp; King County; CDC COVID-19 Investigation Team. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):377-381. doi: 10.15585/mmwr.mm6913e1.</citation>
    <PMID>32240128</PMID>
  </results_reference>
  <results_reference>
    <citation>Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC, Yang P, Wang Q, Peiris M, Poon LLM. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem. 2020 Apr 1;66(4):549-555. doi: 10.1093/clinchem/hvaa029.</citation>
    <PMID>32031583</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020 Jul 28;71(15):793-798. doi: 10.1093/cid/ciaa345.</citation>
    <PMID>32221523</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. PCR Assays Turned Positive in 25 Discharged COVID-19 Patients. Clin Infect Dis. 2020 Apr 8. pii: ciaa398. doi: 10.1093/cid/ciaa398. [Epub ahead of print]</citation>
    <PMID>32266381</PMID>
  </results_reference>
  <results_reference>
    <citation>Li Y, Yao L, Li J, Chen L, Song Y, Cai Z, Yang C. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020 Jul;92(7):903-908. doi: 10.1002/jmv.25786. Epub 2020 Apr 5.</citation>
    <PMID>32219885</PMID>
  </results_reference>
  <results_reference>
    <citation>Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 Mar;25(10). doi: 10.2807/1560-7917.ES.2020.25.10.2000180.</citation>
    <PMID>32183930</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 Mar 28. pii: ciaa344. doi: 10.1093/cid/ciaa344. [Epub ahead of print]</citation>
    <PMID>32221519</PMID>
  </results_reference>
  <results_reference>
    <citation>Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2017 Jan 10;1(1):33-46. doi: 10.1002/gch2.1018. eCollection 2017 Jan.</citation>
    <PMID>31565258</PMID>
  </results_reference>
  <results_reference>
    <citation>Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.</citation>
    <PMID>31995857</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J, Hu Z, Yi Y, Shen H. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-711. doi: 10.1007/s11427-020-1661-4. Epub 2020 Mar 4.</citation>
    <PMID>32146694</PMID>
  </results_reference>
  <results_reference>
    <citation>Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020 Apr 14;323(14):1406-1407. doi: 10.1001/jama.2020.2565.</citation>
    <PMID>32083643</PMID>
  </results_reference>
  <results_reference>
    <citation>Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang QW, Xu SY, Zhu HD, Xu YC, Jin Q, Sharma L, Wang L, Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020 Jul 28;71(15):778-785. doi: 10.1093/cid/ciaa310.</citation>
    <PMID>32198501</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Diego Hernan Giunta, PhD, MPH, MD</investigator_full_name>
    <investigator_title>MD, MPH, University SoTL, PhD</investigator_title>
  </responsible_party>
  <keyword>SARS Virus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Health Personnel</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

